404 related articles for article (PubMed ID: 33039585)
1. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
[TBL] [Abstract][Full Text] [Related]
2. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ; Peyrin-Biroulet L; Sharara AI; Su C; Modesto I; Mundayat R; Gunay LM; Salese L; Sands BE
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):591-601.e8. PubMed ID: 33684552
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program.
Hudesman DP; Torres J; Salese L; Woolcott JC; Mundayat R; Su C; Mosli MH; Allegretti JR
Patient; 2023 Mar; 16(2):95-103. PubMed ID: 36336750
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Quirk D; Wang W; Nduaka CI; Mukherjee A; Su C; Sands BE
Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1821-1830.e3. PubMed ID: 33127596
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials.
Panés J; Vermeire S; Dubinsky MC; Loftus EV; Lawendy N; Wang W; Salese L; Su C; Modesto I; Guo X; Colombel JF
J Crohns Colitis; 2021 Nov; 15(11):1852-1863. PubMed ID: 33884415
[TBL] [Abstract][Full Text] [Related]
8. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
Biedermann L; Dubinsky MC; Vermeire S; Fellmann M; Gardiner S; Hur P; Mundayat R; Panés J; Rubin DT
Inflamm Bowel Dis; 2023 Sep; 29(9):1370-1379. PubMed ID: 36242764
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Sands BE; Taub PR; Armuzzi A; Friedman GS; Moscariello M; Lawendy N; Pedersen RD; Chan G; Nduaka CI; Quirk D; Salese L; Su C; Feagan BG
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):123-132.e3. PubMed ID: 31077827
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore.
Lee SD; Allegretti JR; Steinwurz F; Connelly SB; Lawendy N; Paulissen J; Gecse KB
BMC Gastroenterol; 2023 Feb; 23(1):34. PubMed ID: 36755231
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Sandborn WJ; Lawendy N; Danese S; Su C; Loftus EV; Hart A; Dotan I; Damião AOMC; Judd DT; Guo X; Modesto I; Wang W; Panés J
Aliment Pharmacol Ther; 2022 Feb; 55(4):464-478. PubMed ID: 34854095
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
[TBL] [Abstract][Full Text] [Related]
14. Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program.
Dubinsky MC; Magro F; Steinwurz F; Hudesman DP; Kinnucan JA; Ungaro RC; Neurath MF; Kulisek N; Paulissen J; Su C; Ponce de Leon D; Regueiro M
Inflamm Bowel Dis; 2023 Jan; 29(1):51-61. PubMed ID: 35380664
[TBL] [Abstract][Full Text] [Related]
15. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR; Gecse KB; Chiorean MV; Argollo M; Guo X; Lawendy N; Su C; Mundayat R; Paulissen J; Salese L; Irving PM
J Gastroenterol Hepatol; 2024 Feb; 39(2):264-271. PubMed ID: 37953548
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.
Matsuoka K; Hisamatsu T; Kim HJ; Ye BD; Arai S; Hoshi M; Yuasa H; Tabira J; Toyoizumi S; Shi N; Woo JS; Hibi T
J Gastroenterol Hepatol; 2022 Oct; 37(10):1884-1892. PubMed ID: 35734858
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Sandborn WJ; Armuzzi A; Liguori G; Irving PM; Sharara AI; Mundayat R; Lawendy N; Woolcott JC; Danese S
Inflamm Bowel Dis; 2022 Sep; 28(9):1338-1347. PubMed ID: 34958359
[TBL] [Abstract][Full Text] [Related]
19. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
Farraye FA; Qazi T; Kotze PG; Moore GT; Mundayat R; Lawendy N; Sharma PP; Judd DT
Aliment Pharmacol Ther; 2021 Aug; 54(4):429-440. PubMed ID: 34165201
[TBL] [Abstract][Full Text] [Related]
20. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
Feagan BG; Khanna R; Sandborn WJ; Vermeire S; Reinisch W; Su C; Salese L; Fan H; Paulissen J; Woodworth DA; Niezychowski W; Sands BE
Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1442-1453. PubMed ID: 34614208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
